We are live on ! Find out more
TCM

Tang Capital Management Portfolio holdings

AUM $1.97B
1-Year Est. Return 125.1%
This Fund
S&P 500
This Quarter Est. Return
-9.93%
1 Year Est. Return
+125.1%
3 Year Est. Return
+474.48%
5 Year Est. Return
+595.08%
10 Year Est. Return
+2,831.44%
AUM
$224M
AUM Growth
+$4.84M
Cap. Flow
+$9.56M
Cap. Flow %
4.26%
Top 10 Hldgs %
99.56%
Holding
15
New
–
Increased
4
Reduced
–
Closed
3

Top Buys

Rank Stock Value
1
RXDX
Ignyta, Inc.
RXDX
+$26.2M
2
HRTX icon
Heron Therapeutics
HRTX
+$19.6M
3
LPCN icon
Lipocine
LPCN
+$1.46M
4
ATYR
aTyr Pharma
ATYR
+$297K

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$4.88M
2
OPK icon
Opko Health
OPK
+$3.64M
3
INFI
Infinity Pharmaceuticals, Inc.
INFI
+$2.42M

Sector Composition

Rank Sector Weight
1 Healthcare 87.31%
2 Consumer Discretionary 2.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HRTX icon
1
Heron Therapeutics
HRTX
$86.3M
$112M 49.84%
6,197,198
+1,006,361
+19% +$19.6M
LJPC
2
DELISTED
La Jolla Pharmaceutical Company
LJPC
$48.8M 21.76%
3,052,130
– –
RXDX
3
DELISTED
Ignyta, Inc.
RXDX
$21.5M 9.59%
3,972,800
+3,932,800
+9,832% +$26.2M
BMRN icon
4
BioMarin Pharmaceuticals
BMRN
$11.5B
$7.02M 3.13%
90,215
– –
BABA icon
5
Alibaba
BABA
$269B
$4.77M 2.13%
60,000
– –
NKTR icon
6
Nektar Therapeutics
NKTR
$2.39B
$3.7M 1.65%
17,333
– –
BCRX icon
7
BioCryst Pharmaceuticals
BCRX
$2.37B
$1.22M 0.54%
430,000
– –
LPCN icon
8
Lipocine
LPCN
$17.1M
$790K 0.35%
15,294
+9,412
+160% +$1.46M
ATYR
9
aTyr Pharma
ATYR
$46.4M
$777K 0.35%
19,959
+6,388
+47% +$297K
CLDX icon
10
Celldex Therapeutics
CLDX
$2.77B
$220K 0.1%
3,333
– –
OPK icon
11
Opko Health
OPK
$921M
– –
-350,000
Closed -$3.64M
SRPT icon
12
Sarepta Therapeutics
SRPT
$1.66B
– –
-250,000
Closed -$4.88M
INFI
13
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
– –
-460,000
Closed -$2.42M

Similar funds

HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
SGAM
Smith Group Asset Management Dallas, Texas $1.96B AUM 43.61% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $1.98B AUM 19.17% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $1.98B AUM 1.62% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return

Tang Capital Management's Q2 2016 Portfolio in Review

As of Q2 2016, Tang Capital Management held 15 positions worth $224M, up 2.2% from $220M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Tang Capital Management deployed $9.56M of net new capital in Q2 2016, adding to 4 existing holdings.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 86% a quarter earlier, followed by Consumer Discretionary.

On the sell side, the most notable exit was Sarepta Therapeutics, an estimated $4.88M sold.

  • Tang Capital Management added most to Ignyta, Inc. in Q2 2016, an estimated $26.2M increase.
  • Tang Capital Management fully exited Sarepta Therapeutics in Q2 2016, selling an estimated $4.88M.
  • Tang Capital Management's ten largest holdings make up 100% of its $224M portfolio in Q2 2016.
  • Tang Capital Management opened 0 new positions and closed 3 in Q2 2016.
  • Tang Capital Management's portfolio value rose 2.2% quarter-over-quarter to $224M.

Based on Tang Capital Management's 13F filing for Q2 2016, filed 15 Aug 2016.